Explore the Relationship between the Gut Microbiota and Insulin Resistance/Type 2 Diabetes

^*Correspondence: Maher M Akla, Department of Chemistry, Mansoura University, Mansoura, Egypt, Tel: 201020432031, Email:

Introduction

The human gut is home to a complex and diverse ecosystem of microorganisms, collectively known as the gut microbiota. Recent studies have shown that the gut microbiota plays a crucial role in human health and disease, including the development of insulin resistance and type 2 diabetes. This review will explore the relationship between the gut microbiota and insulin resistance/type 2 diabetes and the potential for microbiota based therapies to treat these conditions [1].

The gut microbiota and insulin resistance/type 2 diabetes

The gut microbiota plays a critical role in the regulation of glucose metabolism and insulin sensitivity. Studies have shown that a lack of beneficial bacteria in the intestine, such as bifid bacterium and Lactobacillus, is associated with an increased risk of insulin resistance and type 2 diabetes.

One mechanism by which the gut microbiota influences glucose metabolism is through the production of Short-Chain Fatty Acids (SCFAs). SCFAs are produced by the fermentation of dietary fiber by gut bacteria and have been shown to improve insulin sensitivity and glucose metabolism in animal and human studies. The gut microbiota also plays a role in the regulation of inflammation, which is a key mechanism in the development of insulin resistance and type 2 diabetes. Dysbiosis, or an imbalance in the gut microbiota composition, has been linked to increased inflamm ation and insulin resistance [2,3].

Description

Microbiota-based therapies for insulin resistance/type 2 diabetes

Microbiota based therapies are emerging as a promising approach for the treatment of insulin resistance and type 2 diabetes. One approach is the use of probiotics, which are live microorganisms that confer a health benefit when consumed in adequate amounts. Studies have shown that probiotics can improve glucose metabolism and insulin sensitivity in animal and human studies. Another approach is the use of prebiotics, which are non-digestible carbohydrates that selectively stimulate the growth and activity of beneficial gut bacteria. Prebiotics have been shown to improve glucose metabolism and insulin sensitivity in animal and human studies. Fecal Microbiota Transplantation (FMT) is another emerging approach for the treatment of insulin resistance and type 2 diabetes. FMT involves the transfer of fecal material from a healthy donor to a recipient with a dysbiotic gut microbiota. While FMT is still in the experimental phase for the treatment of insulin resistance and type 2 diabetes, early studies have shown promising results [4,5].

Conclusion

The gut microbiota plays a critical role in the regulation of glucose metabolism and insulin sensitivity. A lack of beneficial bacteria in the intestine is associated with an increased risk of insulin resistance and type 2 diabetes. Microbiota based therapies, such as probiotics, prebiotics, and fecal microbiota transplantation, have emerged as promising approaches for the treatment of these conditions. However, more research is needed to validate these approaches in clinical trials.

References

1. Ley, Ruth E, Peter J Turnbaugh, Samuel Klein, and Jeffrey I Gordon, et al. "Human gut microbes associated with obesity." Nature 444 (2006): 1022-1023.

   [Crossref] [Google Scholar] [PubMed]

2. Bouter, Kristien E, Daniel H van Raalte, Albert K Groen, and Max Nieuwdorp, et al. "Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction." Gastroenterology 152 (2017): 1671-1678.

   [Crossref] [Google Scholar] [PubMed]

3. Zhang, Xiuying, Zhiwei Fang, Chunfang Zhang, and Huihua Xia, et al. "Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial." Diabetes Ther 8 (2017): 293-307.

   [Crossref] [Google Scholar] [PubMed]

4. Cani, Patrice D, Jacques Amar, Miguel Angel Iglesias, and Marjorie Poggi, et al. "Metabolic endotoxemia initiates obesity and insulin resistance." Diabetes 56 (2007): 1761-1772.

   [Crossref] [Google Scholar] [PubMed]

5. Cani, Patrice D, Rodrigo Bibiloni, Claude Knauf, and Aurelie Waget, et al. "Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice." Diabetes 57 (2008): 1470-1481.

   [Crossref] [Google Scholar] [PubMed]